PFBT
BTAI icon

Parkside Financial Bank & Trust’s BioXcel Therapeutics BTAI Stock Holding History

Parkside Financial Bank & Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151 Hold
112
– – ﹤0.01% 2653
2025
Q4 		$180 Hold
112
– – ﹤0.01% 2641
2025
Q3 		$287 Hold
112
– – ﹤0.01% 2638
2025
Q2 		$203 Hold
112
– – ﹤0.01% 2672
2025
Q1 		$228 Sell
112
-1
-0.9% -$4 ﹤0.01% 2660
2024
Q4 		$674 Hold
113
– – ﹤0.01% 1806
2024
Q3 		$1.1K Buy
+113
New +$1.52K ﹤0.01% 1687

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Parkside Financial Bank & Trust's BTAI Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 112 shares worth $151. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

Parkside Financial Bank & Trust first reported a position in BTAI in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.1K in Q3 2024. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Parkside Financial Bank & Trust held 112 shares of BioXcel Therapeutics worth $151 as of Q1 2026.
  • Parkside Financial Bank & Trust left its BioXcel Therapeutics share count unchanged in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2653 holding.
  • Parkside Financial Bank & Trust first reported a position in BioXcel Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Parkside Financial Bank & Trust's BioXcel Therapeutics position peaked at $1.1K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.